rss-es – Página 17

National Survey Shows Drop in E-Cigarette Use Among High School Students

Murilo Freitas - 17:47, 1 de noviembre de 2023263

National Survey Shows Drop in E-Cigarette Use Among High School Students
http://www.fda.gov/news-events/press-announcements/national-survey-shows-drop-e-cigarette-use-among-high-school-students

rss-es

FDA Proposes to Ban Food Additive, Continues Assessments of Additional Chemicals

Murilo Freitas - 14:01, 1 de noviembre de 2023210

FDA Proposes to Ban Food Additive, Continues Assessments of Additional Chemicals
http://www.fda.gov/news-events/press-announcements/fda-proposes-ban-food-additive-continues-assessments-additional-chemicals

rss-es

Cardinal Health, Inc. Issues Voluntary Nationwide Recall of Certain LEADER™ Brand Eye Drops Supplied by Velocity Pharma, LLC Due to Potential Risk of Eye Infections

Murilo Freitas - 04:00, 31 de octubre de 2023168

Dublin, OH, Cardinal Health, Inc. is initiating a voluntarily recall for all lots of ophthalmic products supplied by Velocity Pharma, LLC to the consumer level. Cardinal Health, Inc. received information from FDA indicating investigators found insanitary conditions in the manufacturing facility and

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/cardinal-health-inc-issues-voluntary-nationwide-recall-certain-leadertm-brand-eye-drops-supplied

rss-es

The Harvard Drug Group, LLC Issues Voluntary Nationwide Recall of Certain Rugby® Laboratories Brand Eye Drops Supplied by Velocity Pharma, LLC Due to Potential Risk of Eye Infections

Murilo Freitas - 04:00, 31 de octubre de 2023258

La Vergne, TN, The Harvard Drug Group, LLC d/b/a Major® Pharmaceutical and Rugby® Laboratories is initiating a voluntarily recall for all lots of Polyvinyl Alcohol, 1.4% Lubricating Eye Drops and Lubricating Tears Eye Drops (Dextran/Hypromellose, 0.1%/0.3%) supplied by Velocity Pharma, LLC to the co

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/harvard-drug-group-llc-issues-voluntary-nationwide-recall-certain-rugbyr-laboratories-brand-eye

rss-es

FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases

Murilo Freitas - 21:55, 30 de octubre de 2023228

FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases
http://www.fda.gov/news-events/press-announcements/fda-approves-interchangeable-biosimilar-multiple-inflammatory-diseases

rss-es

FDA Roundup: October 31, 2023

Murilo Freitas - 21:40, 30 de octubre de 2023263

FDA Roundup: October 31, 2023
http://www.fda.gov/news-events/press-announcements/fda-roundup-october-31-2023

rss-es

Olympus Recalls Olympus High Flow Insufflation Unit Due to Over-Inflation

Murilo Freitas - 04:00, 29 de octubre de 2023231

The Olympus High Flow Insufflation Unit delivers carbon dioxide gas into the abdomen or colon. The unit may over-inflate air into the body with no warning.

http://www.fda.gov/medical-devices/medical-device-recalls/olympus-recalls-olympus-high-flow-insufflation-unit-due-over-inflation

rss-es

FDA Roundup: October 27, 2023

Murilo Freitas - 20:42, 26 de octubre de 2023195

FDA Roundup: October 27, 2023
http://www.fda.gov/news-events/press-announcements/fda-roundup-october-27-2023

rss-es

FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants

Murilo Freitas - 15:06, 25 de octubre de 2023229

FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants
http://www.fda.gov/news-events/press-announcements/fda-raises-concerns-about-probiotic-products-sold-use-hospitalized-preterm-infants

rss-es

Exela Pharma Sciences, LLC Issues Voluntary Nationwide Recall of 8.4% Sodium Bicarbonate Injection, USP, 50 mEq/50 mL, Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL, and ELCYS (cysteine hydrochloride Injection), USP 500 mg/10 mL Due to the Presence of Particulate Matter

Murilo Freitas - 04:00, 24 de octubre de 2023190

Lenoir, North Carolina. Exela Pharma Sciences, LLC, (Exela) is voluntarily recalling the products listed in the table below to the consumer level. Particulate matter identified as silicone was observed during routine inspection of retain samples. Risk Statement: Administration of an injectable pro

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/exela-pharma-sciences-llc-issues-voluntary-nationwide-recall-84-sodium-bicarbonate-injection-usp-50